Nuveen Asset Management’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $24.1M | Buy |
944,601
+8,802
| +0.9% | +$225K | 0.01% | 1050 |
|
|
2024
Q3 | $26.5M | Buy |
935,799
+3,358
| +0.4% | +$95K | 0.01% | 989 |
|
|
2024
Q2 | $24.6M | Sell |
932,441
-45,265
| -5% | -$1.19M | 0.01% | 1001 |
|
|
2024
Q1 | $29.7M | Sell |
977,706
-26,755
| -3% | -$813K | 0.01% | 922 |
|
|
2023
Q4 | $28.2M | Sell |
1,004,461
-26,798
| -3% | -$753K | 0.01% | 926 |
|
|
2023
Q3 | $28M | Sell |
1,031,259
-11,193
| -1% | -$304K | 0.01% | 849 |
|
|
2023
Q2 | $32M | Buy |
1,042,452
+35,919
| +4% | +$1.1M | 0.01% | 782 |
|
|
2023
Q1 | $36.3M | Sell |
1,006,533
-10,222
| -1% | -$368K | 0.01% | 702 |
|
|
2022
Q4 | $40.2M | Buy |
1,016,755
+26,617
| +3% | +$1.05M | 0.02% | 624 |
|
|
2022
Q3 | $39.8M | Buy |
990,138
+9,590
| +1% | +$385K | 0.02% | 625 |
|
|
2022
Q2 | $41.2M | Buy |
980,548
+63,117
| +7% | +$2.65M | 0.02% | 625 |
|
|
2022
Q1 | $35.7M | Buy |
917,431
+6,479
| +0.7% | +$252K | 0.01% | 815 |
|
|
2021
Q4 | $36.3M | Sell |
910,952
-76,583
| -8% | -$3.05M | 0.01% | 862 |
|
|
2021
Q3 | $35.7M | Sell |
987,535
-207,347
| -17% | -$7.49M | 0.01% | 876 |
|
|
2021
Q2 | $49M | Sell |
1,194,882
-3,705
| -0.3% | -$152K | 0.01% | 749 |
|
|
2021
Q1 | $52.3M | Buy |
1,198,587
+793,209
| +196% | +$34.6M | 0.02% | 702 |
|
|
2020
Q4 | $20.3M | Buy |
405,378
+143,379
| +55% | +$7.18M | 0.01% | 1259 |
|
|
2020
Q3 | $11M | Buy |
+261,999
| New | +$11M | ﹤0.01% | 1462 |
|